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Abstract
Cancer is considered as the second cause of morbidity and also mortality, after 
cardiovascular diseases. Despite the immense progress in efficacious biomark-
ers made in the present time, there are very few of them that can timely detect 
cancers or that can predict treatment outcomes or stratify patients according to 
their response to the treatment. Among other modern instruments involved in the 
research of this disease, proteomics emerged strongly, since it analyzes the “molec-
ular effectors.” Although it has some setbacks (like the lack of amplification of the 
signal), it is however one of the best means of investigating the presence and causes 
and predicting the evolution patterns of the disease. This chapter describes briefly 
pre-analytical (pre-MS steps), the main concepts, and the MS equipment used for 
such applications, followed by the presentation of several proteomic applications in 
melanoma, glioblastoma, pancreatic cancer, and colon cancer.
Keywords: proteomics, biomarkers, melanoma, glioblastoma, pancreatic cancer, 
colorectal cancer
1. Introduction
Cancer is a major challenge for health, representing the second leading cause 
of death worldwide. While certain progress was made in diagnostics and in some 
therapies for different cancers, there is still an urgent need for consistent efforts 
in order to set up new biomarkers for the diagnostics, prognosis, or stratification 
of patients. Efforts have been made to identify potential biomarkers by different 
approaches, like the use of techniques of genomics, transcriptomics, metabolomics, 
or proteomics. While the nucleic acid-based techniques present the advantage of 
the amplification potential, but lack the “effector” role, proteomics is considered 
more relevant, since proteome is directly involved in producing effective biological 
effects, yet it lacks the potential of amplification of nucleic acids. So, the detection 
of modifications, quantitative and/or qualitative, mainly affecting, for instance, low 
abundance proteins in biological fluids, requires increased sensitivity equipment 
and eventual strategies to eliminate the high-abundant and less significant ones. All 
these represent a major challenge of today’s proteomics and will be briefly reviewed.
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2. Preliminary steps
One major concern in proteomics is sample preparation, since it is generally 
accepted that this step is generating most of the false discoveries in the field. 
Therefore, we are briefly referring to this step, as well as to pre-MS steps, which 
are dedicated to reducing the sample complexity. Even if we do not address a total 
proteome, the analysis of a plasma proteome or a cellular proteome generates a 
large amount of data. Thus, different strategies of pre-separation are used in the 
proteomic analysis.
Depending on the biological materials used as start materials, it is possible that 
additional depletion technologies are needed, in order to reduce/eliminate major 
proteins (such as serum albumin or immunoglobulins).
One of the best technologies established uses an electrophoretic separation step 
to separate proteins; in earlier years, even the old one-dimensional sodium dodecyl 
sulfate (1D SDS) gel electrophoresis was used for the purpose. The next step in this 
approach was the use of 2D electrophoresis, which is more efficient since it uses the 
combination of isoelectric focusing and mass separation of proteins. The critical 
aspect is the time and material consumption, since for each condition one needs 
several runs to provide statistically significant results. Finally, the more advanced 
two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) was 
developed, which provides a significant reduction of runs (since on each gel three 
distinct conditions can be analyzed, such as sample, control, and sample-control 
mixture), and has about two orders of concentration lower. This last approach 
affords a good detection of low abundance proteins.
Another means of achieving the first separation of proteins is provided by 
capillary electrophoresis (CE). In combination with mass spectrometry (MS), this 
technique allows the detection of proteins [1], as well as glycoproteins [2]; besides 
proteomics, the technology provides in combination with MS solid platform for 
metabolomics studies [3, 4].
More recently, a distinct strategy was adopted, consisting in the proteolytic 
fragmentation of the proteins in samples (i.e., using trypsin), followed by the 
isoelectric focusing of the resulting peptide samples. The process usually uses 
single-use devices that are based on very narrow pH steps for focusing. Usually, 
such devices serve as the “feeder” for the mass spectrometry device, and one can 
obtain a complete picture of the proteins present in the sample.
3. Mass spectrometers for proteomics
Over the past decades, mass spectrometry-based proteomics was developed as a 
fundamental tool in identifying clinically relevant biomarkers for disease progression 
and assessing the organism response to treatment, with better outcome for patients.
Generally, proteomics refers to any kind of large-scale characterization of 
protein species in a sample given by an analytical approach, yet due to its extensive 
use, proteomics becomes quite synonymous with mass spectrometry analysis for 
protein identification, localization, interaction, abundance, and posttranslational 
modifications lately [5]. More specifically, in terms of biomarker discovery, MS 
proteomics usually indicates proteome characterization and comparison among 
various disease-stage models and healthy subjects.
Compared with the genomics or transcriptomics technologies, proteomics 
remained for years limited in terms of throughput and depth [6]. This is due to the 
fact that unlike nucleic acids, proteins cannot be easily amplified which limits the 
detection of the least abundant species in complex biological samples.
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Another challenge is due to protein posttranslational modifications (PTMs). 
PTMs increase the complexity and dynamic range of proteome samples, compared 
to the genome samples, by creating a diversification that reach millions of modi-
fied protein products given the existence of protein isoforms, alternative splicing, 
somatic DNA rearrangements, or proteolytic events [5].
Although recent technological improvements in instrumentation also allow the 
analysis of intact proteins and protein complexes [6–9], there is still limited prog-
ress in adopting top-down MS strategy in a large-scale analysis of proteomes. As a 
consequence, the bottom-up strategy remains the main approach in MS-based pro-
teomics [10]. In bottom-up workflows, proteins are first isolated from the biological 
sample, digested using single or multiple proteases to peptides (depending on the 
aim of the experiment), and then analyzed by mass spectrometry [11].
Due to proteome complexity, most often samples are subject to online separation 
in nano- or capillary C18 reversed-phase systems and even for higher dimensional-
ity to offline or online fractionation using different chemistries at the protein or 
peptide level [12].
Traditionally, ion traps have been employed in discovery studies, in contrast 
to validation steps where triple quadrupole-type instruments have been used for 
targeted quantification in a larger number of samples [13].
Ion traps can store ions by applying multiple electrical fields from different 
directions either effectively “catching” the ions for further fragmentation or eject-
ing them for detection [14].
Nowadays, electrospray ionization (ESI) MS constitutes one of the most power-
ful analytical techniques, being capable of differentiating the pattern, mostly of 
proteins, between tumor and normal adjacent tissues, thus facilitating the elucida-
tion of human tumor molecular fingerprint [15] and understanding the molecular 
alterations that take place during pathological processes.
ESI is a modern ionization technique that brought a big advantage in mass spec-
trometry since it can ionize large nonvolatile molecules without denaturation, keep-
ing non-covalent, receptor-ligand complexes intact. As a soft ionization method, 
which takes place at atmospheric pressure, ESI causes little or no fragmentation of 
the molecules. The principle of the ESI technique is relatively simple: the sample dis-
solved in a polar solvent and possibly with added electrolytes up to a concentration of 
approximately 0.001–10 mM and passes at a slow rate (0.1–30 μl/min) through a very 
thin capillary (10–100 μm) held at a high potential (2–5 kV) that has an open end 
with a sharply pointed tip. Several parameters, among them the solvent, capillary 
shape, desolvation gas pressure and composition, and distance between the capillary 
and the counterelectrode, were found to directly influence the ESI potential value. In 
ESI process, a fine spray of highly charged droplets is generated and directed toward 
the counterelectrode. The droplets, usually smaller than 10 μm across, contain both 
solvent and analyte molecules. Further, by passing the droplets through a heated 
inert bath gas, i.e., nitrogen, the desolvation process occurs up to the moment 
when the surface tension can no longer sustain the charge (the Rayleigh limit). 
Subsequently, a Coulomb explosion takes place (Figure 1), generating the droplet 
disruption concomitant with singly or multiply charged analyte ion formation [16].
In ESI, the charge state of an analyte depends on the molecular structure and 
also on the ionizability of the molecule in a given solvent, and hence on the solvent 
pH, concentration, and composition [17]. In the case of small molecules (molecular 
weight below 2 kDa) such as metabolites, drugs, amino acids, glycans, and short 
peptide chains, only singly to triply charged ions are formed, while for large mol-
ecules like polypeptides and proteins (molecular weight exceeding over 2–3 kDa), 
multi-charged ions are mostly generated in a positive ion mode. Therefore, ESI 
mass spectra display multiple signals associated with species with multiple charge 
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states [17–19]. Although it brings complexity to the interpretation of the spectra, 
the generation of preponderantly multiply charged ions, either positive [M + nH]n+ 
or negative [M − nH]n−, represents a major advantage as it decreases the m/z ratios. 
Thus, larger molecules, i.e., biopolymers such as polypeptides, proteins, nucleic 
acids, anticancer drugs, etc., can be characterized by MS, using almost any type of 
analyzer with which ESI is compatible (Figure 2).
Besides ESI, one of the most frequently used ionization sources in cancer protein 
biomarker discovery is matrix-assisted laser desorption/ionization (MALDI). 
Figure 1. 
The main physicochemical processes of electrospray ionization in positive ion mode.
Figure 2. 
Principles of ion separation in a time-of-flight analyzer.
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Often considered harmonizing to its sister “soft ionization” technique ESI, MALDI 
is based on analyte molecule co-crystallization with an excess of matrix material 
(mainly small organic molecules, present in 100–100,000-fold excess compared 
with sample concentration). After the co-crystals were hit by pulsed laser beam 
(several pulses per nanoseconds), the matrix absorbs the energy of the laser; it 
releases the energy into the sample as heat, causing the sample to vaporize and form 
ions [20]. Typical MALDI devices are equipped with UV N2 lasers with an emission 
wavelength of 337 nm.
The most challenging step when MALDI is used as ionization source is the selec-
tion of the optimal matrix. The matrix must fulfill a series of requirements, such as 
(i) to provide homogenous co-crystals with the analyte molecules, (ii) to be stable 
under high vacuum to prevent its sublimation, (iii) to deliver a high absorbance at 
the emission wavelength of the laser, (iv) to offer a high signal-to-noise ratio for the 
investigated sample (high sensitivity), and (v) to exhibit a low tendency of analyte-
matrix ion cluster formation.
Unlike ESI, the molecules ionized by MALDI are singly charged, a feature which 
greatly simplifies the data analysis. Although vacuum MALDI has the capacity of a 
higher throughput and more tolerance for contaminants than ESI, the loss of labile 
moieties represents the major drawback [20–22]. However, MALDI technique is a 
widespread ionization technique employed in mass spectrometry imaging (MSI). 
MALDI MSI emerged over the last years as a key technology for label-free mapping 
of the spatial distribution of pharmaceuticals or biomolecules, ranging from small 
metabolites to large proteins, in tissue sections [23].
In MALDI MSI, a focused ionization beam is used to analyze a specific region 
of thin tissue slices mounted on conductive microscope slides by generating a mass 
spectrum that is stored along with the spatial coordination where the measurement 
took place. Further, by moving stepwise the sample or the ionization beam and 
full scan of the sample, several thousands of distribution maps, or ion images, are 
generated. By choosing a peak of interest from the combined spectra, the MS data 
maps its distribution across the sample, as a function of x and y locations, revealing 
therefore greater insight and aiding the understanding of molecular makeup and 
regional heterogeneity. Based on the high spatial resolution (>10 μm), fast acquisi-
tion speed, robustness, and relative ease handling, an entire mouse brain can be 
imaged successively in both positive and negative ion modes with 50 × 50 μm2 pixels 
in less than 1 h by using MALDI-TOF-MSI [24].
The remarkable ability of localizing the biomolecules in tissues, even without 
any previous information about them, and of differentiating compounds by molec-
ular weight, all with no need of sample cleanup or chromatography step prior to 
ionization, exponentially expanded the area of MALDI MSI applicability. Therefore, 
the method had recent major contributions in understanding the disorders by track-
ing proteins, lipids, and cell metabolism for correlating the biomolecular changes 
with diseases and improving diagnostics and drug delivery [25].
Although low-resolution instruments such as ion traps can be used for pro-
teome characterization due to their fragmentation flexibility and fast cycle rates 
[26], high-resolution mass spectrometry (HRMS) remains a goal and ambition in 
proteomics. This is because the coeluting ions can overlap when measuring peptides 
in complex biological samples [27], and this can preclude the accurate charge state 
evaluation and quantification [28].
Although, initially, HRMS was available for the expensive Fourier-transform ion 
cyclotron resonance (FT-ICR) and magnetic instruments and only time-of-flight 
(TOF) instruments could be routinely used in facilities [29], developments in the 
late 1990s of technological ion trapping and storage resulted in the design of ion 
orbital trapping—Orbitrap—which allowed HRMS to be attained [30].
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The Orbitrap consists of two outer electrodes (disposed in a special bell-like archi-
tecture) and a central spindle-like electrode between which ions are squeezed using elec-
trical fields [31]. The m/z values are obtained by the Fourier transform (FT) of the image 
current produced by the axial oscillations of the ions injected in the mass analyzer [6].
The initial limiting factor in introducing Orbitrap in the commercial market was 
related to the difficulties in interfacing this system with ion sources such as electro-
spray ionization [32], but adding a curved ion trap, subsequently termed C-trap, 
for ion injection and coupling linear ion traps (LTQ ) with Orbitrap, resulted in the 
introduction of a hybrid instrument which offered a good balance between speed, 
sensitivity, and resolution [33], as most of the methods in proteomics used HRMS 
for precursor mass measurement and the ion trap for ion fragment scanning.
Using this setup, it was possible to obtain an almost complete proteome mapping 
for several simpler organisms such as E. coli or yeasts in just a few hours [34–36].
Although it did not provide a complete proteomic map for more complex organ-
isms, this had a significant impact in the characterization of proteomic signatures in 
many eukaryotic cell lines such as melanoma cells.
Mass spectrometry was found to be effective also in proteomic phenotyping of 
melanoma cell lines [37]. For example, Pirmoradian et al. reported the identifica-
tion of more than 5000 protein groups in A375 human melanoma cell line using 
4-h-long optimized gradients without any prefractionation [38]. They were able 
to reach this depth of the proteome using a relatively recently commercially intro-
duced instrument setup which coupled the Orbitrap mass analyzer with a quadru-
pole mass filter and an enhanced FT deconvolution algorithm [39].
Besides proteomics, the hybrid platform is also instrumental in the assessment 
of the dynamics of protein interactions in the pathological context of melanoma 
[40]. This is important, since it was shown that mutations in p53 oncogene could 
alter its interaction partners leading to protein complexes that promote invasion 
and migration of tumor cells [40–42].
4. Melanoma biomarkers
The introduction of the Orbitrap mass analyzer allowed routine HRMS to be 
also used for biomarker discovery studies. Using an LTQ-Orbitrap, Kawahara et al. 
defined the phenotypic differences in the secretome of melanoma, carcinoma, and 
noncancerous cells [43]. It is interesting to note that the top two candidates from the 
carcinoma secretome were validated in the saliva of patients using pseudo-selected 
reaction monitoring (pseudo-SRM) experiments on the same conventional hybrid 
instrument, usually dedicated only to the discovery approach, which subjects the 
flexibility and the impact of this platform.
Counting about 55,500 deaths annually, cutaneous melanoma represents the 
most aggressive type of skin cancer [44]. In principle, melanoma biomarkers can 
provide insights into either the overall outcome of this disease or to the therapeutic 
response to available treatments, being classified as prognostic biomarkers, predic-
tive biomarkers, and on-treatment biomarkers [45]. However, to date a relatively 
low number of melanoma biomarkers were found, making it difficult to predict 
the outcome in patients. Moreover, their expression levels change with the stage 
of the disease [46]. Importantly, melanoma seems to have the highest mutational 
load, and once it appeared it becomes life-threatening [47]. Several mutations 
are frequently linked to cutaneous malignant melanoma, and these mutations are 
presented in more than 85% of all new diagnosed melanoma cases.
Stable isotope labeling with amino acids mass spectrometry (SILAC-MS)—
involving incorporation of labeled amino acids into all cell proteins—was recently 
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used in melanoma biomarker discovery. The main advantage of this method is its 
quantitative accuracy and reproducibility [1]. Using SILAC coupled with nano-
spray tandem MS, Liu et al. highlighted several differentially expressed proteins in 
MA2 cells. It is the case of CUB-domain-containing protein 1 (CDCP1), a surface 
marker especially expressed on cells with high metastatic feature [48]. The group 
of Janostiak performed SILAC and tried to identify potential MELK targets. They 
identify MELK as a regulator of the NF-kB pathway with implications in tumor 
survival. MELK inhibition blocks melanoma growth; therefore, it can be viewed as 
a potential therapeutic target [49].
One of the most interesting approaches in cancer research is the possibility of 
performing proteomics on formalin-fixed paraffin-embedded (FFPE) tissues in order 
to denote disease-state-linked molecular fingerprints. This is significant given that 
clinical research units collect patient tissue and usually process them for histopathology 
analysis by FFPE which cross-link protein amino acids for long-term storage [50–53]. 
Using an LTQ-Orbitrap system and a spectral count-based quantitative strategy, [54] 
report the identification of a comprehensive list of 171 possible disease-state-linked 
melanoma biomarkers that were found as differently expressed proteins between the 
three analyzed stages of melanoma: benign nevi, primary, and metastatic melanoma. 
Quantitative MS analysis was also performed by Sengupta’s group to study histone post-
translational modifications in melanoma cells. Considering their findings EZH2 (his-
tone methyltransferase) was upregulated in both FFPE samples and melanoma cell lines 
in concordance with increased histone H3 lysine 27 trimethylation [16]. Despite the 
potential to give a more appropriate insight into melanoma environment, this technique 
presents some limitations due to formalin-induced covalent linkage of proteins [55].
An even more exciting perspective of HRMS is the investigation of PTMs—as 
these can impact protein folding, traffic, degradation, signaling pathways, and 
ultimately cellular response [56]. This is of special interest given that these modi-
fications cannot be captured by genomics or transcriptomics studies, while the 
biomarkers for cancer could be also affected by such modifications.
Using multienzyme digestion and different fragmentation techniques [57] 
available on the hybrid ion trap-Orbitrap platform, Chiritoiu et al. reported the 
occupancy of all N-glycosylation sites of tyrosinase in a melanoma cell line [58], an 
enzyme shown to be correlated with patient clinical evolution in melanoma [59, 60]. 
Moreover, recent evidence suggests that even other members of the tyrosinase-
related protein family could be also linked to melanoma progression [61, 62].
An emerging field in biomarker discovery is MSI in which the analysis is 
performed directly on frozen tissue in order to evaluate possible disease-specific 
molecular fingerprints. It was already shown that MSI could be performed using 
both low- and high-resolution instruments [63–65] but also using the Orbitrap 
technology [66]. Even more, Rao et al. [67] showed that this technology can be 
implemented on the conventional platform of hybrid instrument LTQ-Orbitrap. 
MSI technology would be useful in diagnosing difficult melanocytic lesions in skin 
cancer [68]. Lazova and Seeley showed that this technology could differentiate Spitz 
nevi (an uncommon form of skin mole) from Spitzoid malignant melanoma. Even 
more, in a recent study, the same author reported a histopathological misdiagnosed, 
congenital malignant melanoma that on a more detailed look by MSI revealed 
evidence of a congenital melanocytic nevus with proliferative nodules [69]. These 
reports underline the potential impact that mass spectrometry could have in the 
clinic, as the next focus is on the clinical applications of this technology [70].
BRAFV600E/K mutation is a major oncogenic driver with a frequency of 
40–60% between patients diagnosed with advanced melanoma cancer. This 
mutation is commonly associated with MAP kinase pathway activation. In this 
sense BRAF blockade therapy is usually combined with MEK inhibitors. In BRAF 
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wild-type cells, BRAF inhibitors are likely to lead to MAP kinase activation and thus 
are not advised for association [70, 71].
NRAS mutant melanoma is known as the second most common mutation 
observed in melanoma. Recent studies indicated that stage IV NRAS patients have a 
shorter overall survival rate than those with wild-type form [72].
New melanoma-related biomarkers were discovered using proteomic analysis 
of five melanoma cell lines. Two of these are represented by vimentin and nestin, 
intermediate filament proteins involved in cell migration, apoptosis, and cytoskel-
etal organization. Vimentin may play an important role in migration and invasion. 
Studies indicated that those cells close to blood vessels present higher levels of vimen-
tin. Together with vimentin, the nestin level can be correlated with the aggressiveness 
of the tumor. Both were validated as melanoma-related proteins using samples from 
40 patients with different stages of melanoma. These two proteins can be viewed as 
potential biomarkers to distinguish between different forms of melanoma [73].
A recent study reveals a potentially new biomarker, SerpinE2, responsible for 
the invasive phenotype of melanoma slow-cycling cells. Proteome analysis reports 
two other proteins enriched in melanoma cells, PDGFRL and BMP1 [47].
Microphthalmia-associated transcription factor (MITF) expressed by mela-
noma cells is known as a driver of melanoma progression. It is involved in multiple 
biological processes like proliferation and differentiation. Due to its high sensitivity 
and specificity, this transcription factor is frequently used to differentiate highly 
proliferative melanoma cells from poorly invasive population [74].
Al-Ghoul et al. performed a comparative analysis of proteins expressed by either 
primary melanoma cells or metastatic cells. Their results indicate higher abundance 
of metabolic proteins upregulated in melanoma cells. About 131 proteins have a 
higher level than normal in these cells. Cyclophilin A, a protein linked to cancer 
progression and inflammatory diseases, was also identified to be upregulated in 
metastatic melanoma [75].
Histopathologic characteristics of 10 samples originating from patients with 
stage III metastatic melanoma were correlated with protein expression obtained 
using mass spectrometry. Authors define four proteins positively correlated to 
melanoma tumor, and among them are melanoma cell adhesion molecule (MUC18), 
melanoma chondroitin sulfate proteoglycan (CSPG4), melanoma-associated 
antigen D2, and melanocyte protein (melan A) [76].
S-100β serum level can reflect clinical stage. In general its concentration is 
less than 0.10 μg/L in healthy population. Usually S-100β level is used to monitor 
the response to treatment in patients with metastatic tumor. A second prognostic 
biomarker largely used is LDH, a well-known prognostic factor commonly used in 
those patients diagnosed with stage IV melanoma [46].
Based on the assumption that eIF4A1 and eIF4E are overexpressed in cancer 
cells, Joyce et al. tried to elucidate the possible mechanism related to invasive 
phenotype of cancer cells. Silencing either eIF4A1 or eIF4E reduces melanoma 
proliferation. Recent findings reveal that eIF4A1-depleted melanoma cells and 
eIF4E-depleted melanoma cells may present quite different proteomes, which may 
lead to hypothesis that they induce invasive phenotype through alteration of differ-
ent molecular mechanisms. In order to perform this comparative proteome analysis, 
a MS operating in MS3 mode was used [77].
5. TOF MS applications to biomarkers of human glioblastoma
Discovery and implementation of these fragmentation techniques, together with 
ESI and MALDI, revolutionized the field of MS, bringing significant contributions 
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to the development of its analytical potential and its successes toward the topic of 
great interest, such as neoplastic transformations.
Accounting for 60% of all primary brain tumors, astrocytomas are already the focus 
of research for a few years [78]. Of these, glioblastoma multiforme (GBM), classified 
by World Health Organization (WHO) as having the highest malignancy degree, grade 
4, is one of the most common and aggressive malignant brain tumor [79]. Treatment 
of GBM consists of surgical resection, radiation, and chemotherapy. Unfortunately, 
patients with this type of tumor have a median survival of approximately 14–15 months 
from the diagnosis [80, 81], with an estimated 5-year survival rate of 5%.
This poor prognosis could be allied to the richly neovascularized solid tumor 
profile, with many upregulated angiogenic and mitogenic factors [82], in other 
words, the high infiltrative and diffuse spreading of the GBM cells over long 
distances in the brain.
In recent years considerable efforts were invested in understanding the molecu-
lar mechanisms governing GBM tumorigenesis and also for the discovery of novel 
and more efficient therapeutic targets [83].
Astrocytomas and especially GBM were intensively addressed by proteomic 
studies, particularly by two-dimensional polyacrylamide gel electrophoresis 
(2D-PAGE), followed by protein digestion in a bottom-up approach. Nevertheless, 
the high sensitivity and reproducibility of MS, the need for significantly fewer 
test materials, as well as the MS relative simple working procedure over 2D-PAGE 
evolved MS as a powerful tool in screening cellular and tissue protein expression 
profiles (Figure 3) [84].
Figure 3. 
Basic analytical strategies in proteomics.
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In 2005, the proteome investigation in a single GBM tissue sample conducted by 
Wang et al. employing the combination of capillary isoelectric focusing (CIEF) and 
reversed-phase chromatography for multidimensional peptide separation hyphen-
ated to QTOF MS led to the identification of a total of 6866 fully tryptic peptides, 
corresponding to 1820 distinct proteins [85].
MALDI-TOF-MS protein profiling has been used by Schwartz et al. to determine 
protein expression patterns that distinguish primary gliomas from normal brain 
tissue and one grade of gliomas from another, with high sensitivity and specific-
ity. From the total of 162 tissue samples from 127 patients, including 19 patients 
undergoing resective surgery for nonneoplastic disease, 29 grade 2, 22 grade 3, and 
57 grade 4 glioma patients that were analyzed, over 100 potential, tumor-specific 
biomarkers were identified. With their approach, they have distinguished glioma 
grades with high accuracy ranging from 76% to 97%, encountering some difficulty 
in distinction between the WHO grade II and III tumors [86].
A complex protein data set for GBM from direct tissue analysis including 2660 
proteins with a significant number of peptide hits in total and 1401 validated 
protein hits with at least two unique peptide identifications was provided by the 
group of Huber CG [87]. Their novel methodology was based on the application of 
ion-pair RP chromatography to fractionate intact proteins from the tumor tissue 
prior to identification by MALDI-TOF/TOF-MS2, as well as the combination of 
intact protein fractionation with shotgun proteomics to discover the most complex 
data set of proteins.
Considering the limited accessibility to healthy brain tissue samples, especially 
from the same patient, achieving a normal vs. diseased brain comparison at the 
proteome level is challenging. Most of the time, for such investigations, control 
brain tissues are obtained by surgery from patients with epilepsy or autopsy. In 
order to identify and characterize proteins that are differentially expressed in GBM 
and gather information on interactions and functions that lead to this condition, ten 
GBM tumors (patients from 48 to 67 years) and ten epileptic brain tissue (patients 
from 21 to 61 years) samples were analyzed by Mirza and Shamim [88]. By SDS 
PAGE fractionation with internal DNA markers followed by liquid chromatography-
tandem MS [87] on a LTQ-Orbitrap Velos, differential protein expression in GBM 
was identified. These proteins, highly specific to GBM irrespective of their location 
in the brain (right or left temporal region of the brain), were further characterized 
by Ingenuity Pathway Analysis (IPA) to assess protein interactions, functions, and 
upstream regulators. Such an approach provided several other upregulated proteins, 
such as SERPH, PDIA1, CERU, TENA, VTNC, APOE, LEG1, HRG, and FKBP5, 
identified to be involved in tumor progression, aggressiveness, and invasion in 
GBM. Besides the known GBM-associated proteins, CLIC4, NP1L1, IGKC, TAGL2, 
and YES, previously correlated with processes promoting cancer progression, were 
identified here as novel potential biomarkers of GBM [83].
Despite the significant efforts invested over the past decades in finding an 
appropriate treatment for GBM, almost all GBMs are ultimately resistant to 
existing treatment and inevitably recur [89]. Though a multimodal approach 
including surgery, postoperative radiotherapy, and chemotherapy is applied, the 
prognosis for patients with GBM remains rather poor. Hence, there is an urgent 
need for a better understanding of the molecular mechanisms associated with 
GBM, improvement of conventional treatment modalities, and/or development of 
new and more efficient ones. A first step in breaking the evolution and/or recur-
rence of this fast-growing tumor is the development and application of new, rapid, 
and accurate approaches to assess the treatment of biological effects, given that 
currently, the treatment results are radiologically evaluated several months after 
treatment.
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Surface-enhanced laser desorption/ionization (SELDI) TOF MS demonstrated 
its ability in detecting the changes in protein patterns in GBM tumor tissue follow-
ing radiotherapy. In the study reported by Wibom et al. [90], rat BT4C glioma cells 
were implanted into the brain of two groups of 12 BDIX-rats, one of the groups 
receiving radiotherapy. The expression of proteins in normal and tumor brain 
tissue, pooled at four different time points after irradiation, was investigated using 
SELDI TOF MS by principal component analysis (PCA) and partial least squares 
(PLS). The variations over time in protein expression identified by the authors, 
together with the tumor progression in vivo and, last but not least, the rapid and 
significant changes in the protein expression following irradiation, allowed the irra-
diated tumors to be clearly distinguished from the nontreated tumors. Therefore, 
the authors consider that the 77 identified signals characterized by different 
intensity levels in irradiated vs. nonirradiated tumors validate SELDI TOF MS as a 
method of choice in elucidating biological events induced by radiation which can 
be used as markers for monitoring the efficacy of radiation treatment in malignant 
glioma [90].
The pioneer study in which MRI was used to guide proteomic analysis with 
SELDI TOF MS in human GBM in order to demonstrate a correlation between 
imaging patterns and protein expression profiles belonged to Hobbs et al. [84]. 
Contrast-enhanced (CE) magnetic resonance imaging (MRI) represents an impor-
tant diagnostic tool for correlating molecular pathophysiology with the clinical 
management of disease; it can supply elevated spatial resolution and molecular 
signatures of both healthy and diseased tissues in solid tumors. For the identifica-
tion of CE and nonenhanced (NE) regions of the tumor in the four patients previ-
ously diagnosed with GBM, intraoperative stereotaxis during surgical resection 
in conjunction with MRI was used. Further, Hobbs et al. investigated the profile 
of over 100 proteins and peptide species within GBM tumors and compared the 
protein profiles between the CE and NE regions across four patients with MR 
images and confirmed diagnosis of GBM. This CE and NE comparative approach on 
the GBM proteomic fingerprint revealed qualitative and semiquantitative proteomic 
pattern differences, hinting an impaired gene expression profile that correlates with 
detectable tissue imaging parameters [84].
Although noninvasive imaging techniques have improved the neuroradiological 
diagnostic accuracy, in some cases, comprehensive specificity for discrimination 
of brain tumors and detection of minor differences in tumor size and behavior are 
difficult using imaging approaches [91]. Besides, tumor tissue extraction through 
biopsy or resection is not always feasible. For such reasons, identification of reliable 
biomarkers in the blood would facilitate the management process of GBM patients, 
allowing an early diagnosis, establishment of surgical intervention plans, and 
monitoring of the disease course and the treatment response.
Quantitative comparisons of the plasma proteomes of 14 GBM patients and 15 
healthy controls using sequential window acquisition of all theoretical fragment ion 
spectra (SWATH) MS analyses were conducted for identifying potential biomarker 
candidates in plasma of GBM patients. SWATH MS, characterized by high repro-
ducibility and reliability of quantitative information, combines a highly specific 
data-independent acquisition [38] method with a novel targeted data extraction 
strategy to mine the resulting fragment ion data sets [92].
Being a label-free analysis, SWATH MS was employed by Miyauchi et al. in 
conjunction with LC-MS/MS using a Triple TOF 5600 for generating a protein 
quantification method, called quantitative targeted absolute proteomics (QTAP) 
[91]. With the current approach, the authors not just estimated the origin of 
upregulated biomarker candidates in GBM plasma but also have examined if 
the upregulated biomarker candidates were elevated in GBM tissues, and if the 
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biomarkers were detectable in cyst fluid. Additionally, the relationships between 
the concentrations of biomarker candidates in plasma and the clinical presentation 
(tumor size, progression-free survival time (PFS), or overall survival time (OS)) of 
GBM patients were inspected for establishing the relationships between biomarker 
candidates and GBM biology. While LRG1, C9, CRP, SERPINA3, and APOB were 
identified by SWATH MS and QTAP analyses as upregulated biomarker candidates, 
compared with the healthy plasma, GSN, IGHA1, and APOA4 were identified as 
downregulated biomarker candidates (Miyauchi et al.). All the candidate proteins, 
except for CRP, were found to be highly expressed in cytosol of GBM tissues vs. 
noncancerous brain tissues, while GSN was identified as decreasing also in cerebro-
spinal fluid (CSF). Although valuable information was gained by SWATH MS and 
QTAP, in order to determine the feasibility of their findings in clinical application, 
the authors recommend further investigations using plasma from patients with 
postoperative GBM, glioma, and other various types of cancer [91].
Since in 2010, there was no CSF biomarker in clinical use in malignant brain 
tumors, neither for diagnostic nor for other purposes. The detection of recur-
rence or reaction to adjuvant therapy and the exploration of CSF originating 
from GBM patients in respect to peptide profiling were not experimented as well. 
Eleven CSF samples collected by lumbar puncture from four female and seven 
male patients with a single supratentorial GBM manifestation (median 68 years, 
range 43–79 years) and 13 samples from four female and nine male participants 
with mostly spinal canal stenosis, and used as control, were involved in a study 
conducted by Schuhmann and colleague [93]. The peptides, previously separated 
by RP HPLC in 96 fractions per sample, were resuspended in matrix solution 
consisting of α-cyano-4-hydroxycinnamic acid and L-fucose (co-matrix) in 0.1% 
acetonitrile/trifluoroacetic acid (1:1 v/v) and screened by nanoESI-QTOF-MS/
MS. To detect possible marker candidates, the two peptidomes were compared 
using the differential peptide display approach. Additionally, patient data including 
age, duration of symptoms, and the morphological MRI data were correlated to the 
mass spectrometric signal intensity of the peptides in CSF using Spearman’s rank 
correlation coefficient. More than 6000 peptide signals, corresponding to at least 
2000 different peptides, were remarked in the peptide master displays of the two 
peptidomes. Of these, four CSF peptides, specific C-terminal fragments of α-1-
antichymotrypsin, osteopontin, and transthyretin as well as a N-terminal residue of 
albumin, significantly distinguished GBM from controls in all applied statistic tests. 
Although these molecules are components of normal CSF, none of these peptides 
or their precursors was previously reported as significantly elevated in CSF of GBM 
patients.
Although neuronavigational guidance by MRI or positron emission tomography 
(PET) aids in localizing the tumor tissue, the brain shift and tissue deformation 
may negatively influence the accuracy of resection [94, 95]. An option to overcome 
these limitations is the application of intraoperative imaging; however, besides 
being expensive they increase the surgery time [95].
Since the introduction of fluorescence-guided surgery (FGS) in 1998 by 
Stummer et al. subsequent to proagent 5-aminolevulinic acid (5-ALA) treatment, 
contrast enhancement by a fluorescent dye has progressed and represents today an 
important and powerful technique in GBM resection [94, 95]. After oral application 
of 5-ALA approximately 3 h before anesthesia, in a dose of 20 mg/kg body weight, 
the small molecule crosses the abnormal blood-brain barrier into the peritumoral 
tissue and accumulates within the tumor. As a precursor of heme B, in an intermedi-
ate step of the heme biosynthesis cascade, 5-ALA is converted to protoporphyrin IX, 
a red fluorescent at 635 nm upon blue light excitation. Since high-grade gliomas are 
known to be characterized by augmented cell proliferation, tumor cell density and 
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microvessel density, the greater fluorescence intensities generated by accumulation 
of high cellular PpIX concentrations, improve differentiation of tumor from healthy 
brain tissue during intraoperative fluorescence microscopy [95–97]. Nevertheless, 
in some cases, false-positive and false-negative fluorescence results cannot be 
excluded. Hence, molecular and elemental MSI was introduced as a complementary 
technique to examine the potential chances and boundaries of fluorescence diagno-
sis. Within the molecular MSI domain, MALDI MS was demonstrated to have a high 
applicability, even of FGS for meningioma, since it accomplishes the investigation 
of intact molecules by soft ionization [98].
A comprehensive study on the fluorescent drug PpIX and the biosynthesis end 
product heme B, based on MALDI MSI followed by quantitative Fe analysis via 
laser ablation inductively coupled plasma (LA-ICP) MS, was performed by Kröger 
et al. in the group of Karst [95]. Three GBMs after and two GBMs without 5-ALA 
administration, one gliosarcoma (GSM), one low-grade glioma, and two reactive 
brains were characterized using an ion trap-TOF mass analyzer and α-cyano-4-
hydroxycinnamic acid as matrix for MALDI.
With their approach, Kröger et al. enabled the detection of PpIX distribution in 
GBS, where high tumor density exhibited intense PpIX signal during surgery. Heme 
B and enhanced Fe accumulation was detected only in regions of blood vessels and 
hemorrhage, corroborating the hampered transformation from PpIX to heme B in 
GBM tissue. In the case of GSM, the absence of PpIX accumulation determined by 
the nonfluorescent appears during FGS, generated a false-negative fluorescence 
diagnosis [95].
Although initially reported in 1895, GSM, a rare primary neoplasm of the CNS, 
did not gain a broad acceptance until 1955, when three cases of patients with this 
malignancy were described in detail [99]. Thus, hitherto, only a limited number of 
case reports and researches were published, and from those, just a few were target-
ing the identification of potential biomarker species in GSM.
Defined by the WHO as a variant of GBM, accounting for about 2% of all the 
GBM, GSM affects preponderantly the adult population in the fourth to the sixth 
decade of life, more frequently males than females (male/female, 1.8:1) [79]. 
Consisting of alternating areas displaying glial and mesenchymal (sarcomatous) 
differentiation, GSMs are typically located in the cerebral cortex, involving the 
temporal, frontal, parietal, and occipital lobe in decreasing frequency [100]. 
The epidemiology and natural history of this rare malignancy appears similar 
to GBM, with a slightly greater predisposition for temporal lobe involvement. 
As for GBS, the prognosis for GSM after surgical resection and chemotherapy is 
limited, even inferior to those observed in GBM patients, with a median survival of 
11–12 months, with less than 10% survival after 2 years following diagnosis [101]. 
Such a reduced life expectancy may be caused by the widespread penetration of the 
GSM cells into the brain tissue that makes the tumor cells slightly inaccessible to 
treatment methods and so the treatment fails [102].
It is broadly accepted that abnormalities in glycoconjugate glycosylation path-
ways are responsible for atypical cell surface—glycocalyx—molecular structure, 
and the latter one accompanies malignant alteration of cells. Since the cell surface 
carbohydrates are involved in a variety of interactions of the cell with its extracel-
lular environment, any change in their expression cause tumor cell migration, 
metastasis, and invasiveness [103].
In view of the range of glycosyl epitopes that designate tumor-associated 
antigens [104, 105], some of them endorsing proliferation and metastases and some 
suppressing the tumor progression [106], surveying the changes in the profile of 
the glycoconjugate molecules liable for such effect, represents an alternative to the 
proteomic studies. Atypical glycosylation associated with oncogenic transformation 
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was first confirmed with gangliosides [107]. Gangliosides (GGs) are sialic acid-con-
taining glycosphingolipids integrated into the outer leaflet of the cellular membrane 
bilayer and predominantly enriched in microdomains.
Within the intermolecular interactions and through glycosynapses, GGs are 
known to regulate the cell-cell recognition and intercellular adhesion and to modu-
late signal transduction pathways. The stimulation of cell growth inhibition and 
cell differentiation and/or apoptosis of certain GGs is well demonstrated for nearly 
two decades [108]. For instance, the cell number in primary cultures of high-grade 
human GBM, ependymomas, mixed gliomas, astrocytomas, oligodendrogliomas, 
and gangliogliomas, as well as of the rat 9 L cell GSM cell line, was shown to 
decrease following treatment with GM3. In the same time, it had a slight effect on 
the cell number in cultures of a normal human brain [100]. Given the correlation 
of different malignancy grade and median survival time with GG composition and 
content in different types of glioma tumors, GGs can be considered as tumor mark-
ers and used as therapeutic targets or vaccine development [109].
A diminished amount of complex GGs in tumors is connected to the dedifferen-
tiation processes, reflecting the GG pattern alteration in ontogenesis during dif-
ferentiation of nervous tissue: an increased content of complex GGs and a reduced 
volume of simple GGs [110, 111].
Together with the immunochemical and immunohistochemical methods, several 
other biophysical techniques were introduced over the years for mapping and struc-
tural analysis of GGs in different gliomas, such as HPLC, infrared spectroscopy, and 
confocal microscopy via anti-GG monoclonal antibodies [112–114]. Additionally, 
the implementation of miniaturized, integrated devices for sample infusion into 
MS simplified the laborious chemical and biochemical MS strategies by reducing 
sample handling and sample loss, eliminating potential cross-contamination, and 
increasing ionization efficiency and quality of spectra as well as the possibility to 
perform unattended, high-throughput experiments [115]. The world’s first fully 
automated nanoelectrospray system and perhaps the most popular and widely 
used device is the NanoMate robot produced by Advion BioSciences (Figure 4), in 
which 100 or 400 nanospray emitters are integrated onto a single silicon substrate, 
from where electrospray is established perpendicular to the substrate. Considering 
the (i) automated infusion into MS at low flow rates in the nanoliter range (only 
50–100 nL/min), (ii) minute amount of sample, (iii) technical quality of the nano-
sprayers, (iv) reproducibility of the experiment, (v) formation of preponderantly 
multiply charged ions, and (vi) minimized in-source fragmentation of labile groups 
attached to the main structural backbone, in some cases, chip-based devices not 
just eliminated the need for separation prior to MS analysis but also provided more 
robust and quantitative analyses than LC- or CE-MS [116].
The first investigation of GG pattern in a human GSM specimen by sensitive 
and accurate MS methods, complemented by HPTLC analysis was conducted in 
2006 [100]. The current approach was developed and optimized in order to detect 
and structurally characterize the tumor-associated species, which might serve as 
potential diagnostic markers or specific target molecules for the production of anti-
tumor therapeutic agents. Primarily, the densitometric analysis conducted in two 
complex GG mixtures, one originating from a 47-year-old male presenting GSM 
tumor and one from adult frontal cortex used as control, indicated a severalfold 
decrease (7.4×) of the total GG content in GSM vs. normal human brain (Figure 5), 
which was in agreement with previous reports on other glioma types. Further, by 
employing chip-based nanoESI QTOF MS and ultrahigh-resolution nanoESI FTICR 
MS, Vukelić et al. demonstrated for the first time the reduction in the total GG 
content and the altered pattern in GSM vs. control tissue [100]. While GM1a, GD1a, 
and GD1b abundances were very low in GSM, GD3 species were found to account 
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for nearly 50% of the total GG content, being the most emphasized fraction and 
the only one expressed in higher absolute concentration than in normal cortex 
(approximately 128%). Therefore, the authors hypothesized that the combina-
tion of both lower overall biosynthetic rate, due to change in expression of certain 
glycosyltransferases, and higher turnover rate is responsible for such a pattern. At 
the same time, the considerably higher amount of potentially proapoptotic GD3 
than of the O-acetyl GD3 species observed by the authors supported the assumption 
of Kniep et al. [117], according to which, O-Ac-GD3 could by itself be responsible 
Figure 4. 
NanoMate robot with fully automated chip-based ESI (courtesy of Advion BioSciences).
Figure 5. 
Compositions of GGs isolated from human gliosarcoma specimen (A) and normal human frontal 
cortex (B), as revealed by HPTLC followed by densitometric scanning. Reprint with permission from 
Vukelić et al. [100].
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for the protection of tumor cells from apoptosis. Moreover, the high sensitivity and 
mass accuracy of QTOF and FTICR MS and MS/MS permitted them the assignment 
of unusual GG minor species. Among these species, GM4, Hex-HexNAc-nLM1, 
Gal-GD1, Fuc-GT1, GalNAc-GT1, O-Ac-GM3, di- O-Ac-GD3, O-Ac-GD3, and 
O-Ac-GT3, considered as brain developmental antigens [118], were not reported 
previously as glioma-associated structures [100]. The fully CID sequencing at low 
energies of O-Ac-GD3(d18:1/20:0), exhibiting higher abundance in GSM vs. normal 
human brain, provided structural evidence to postulate a novel O-Ac-GD3 isomer, 
O-acetylated at the inner Neu5Ac-residue, previously not structurally confirmed.
In order to reveal the role of GG as tumor-associated antigens, a detailed depic-
tion of native GG mixtures from normal human brain (NB), GBM and correspond-
ing peritumoral tissue [119], was conducted recently by HPTLC and MS [110]. 
Particular attention was paid to the GG expression in PT, since the biochemical 
processes occurring within this area are believed to be responsible for aggressive 
infiltration of tumor cells into the surrounding brain tissue and therefore for high 
incidence of GBM recidivism and poor prognosis of GBM [110, 120].
While the frontal cortex of a 54-year-old who died in a traffic accident was used 
as control, the GBM and the corresponding PT were collected from a 70-year-old 
female patient, whose brain MRI showed an infiltrative tumor lesion measuring 
47 × 43 × 40 mm in the right frontal and insular region. This approach revealed 
distinctive changes in GG expression in GBS. Total GG content in GBS was 
approximately five times lower than in the NB, while approximately two times 
lower than in the PT. For MS analyses, the extracted GG mixture dissolved in 
methanol up to 0.8 mM concentration was infused into a Bruker amaZon ETD ion 
trap system. Whereas predominantly C18 chains were found to characterize the NB 
and PT, shorter (C16) and longer (C22, C24), unsaturated (C24:1) and with odd 
number carbon atom (C17, C19) fatty acids residues were detected in GBS [110]. 
The most abundant GG in GBS (accounting for 53% of the total GG content) was 
GD3(d18:1/18:0), followed by GD3(d18:1/24:0) that was exclusively detected in 
GBS tissue. Likewise, proportions of GM3, GM2, GD2, and O-Ac-GD3/nLM1 were 
much higher in GBS than in the PT and NB tissue. In contrast, GM1, GD1a, GD1b, 
and GT1b constituted the most abundant GG structures in NB, their amount being 
considerably lower in GBS compared to NB and PT. The content of GGs modified 
by O-acetylation, most often of the sialic acid, was also found altered in GBS. The 
previous reports, according to which O-acetylation exhibits antagonistic effect on 
GD3 function, thus modulating its activities [121] and protecting the cell from its 
proapoptotic activity [122], herein confirmed (i) the high intensity of O-Ac-GGs 
in healthy brain tissue, (ii) the low concentrations in PT, and (iii) the detection of 
only one ion corresponding to O-Ac-GT1(d18:1/18:0) in GBM sample. O-Ac-GD1 
was detected in NB and PT, but not in GBS, while O-Ac-GD3 species were found 
exclusively in GBS.
6. Applications of MS in pancreatic cancer (PDAC)
Although it has a lower incidence and prevalence compared to other cancers, 
PDAC is one of the deadliest, patients affected by PDAC having a very low life 
expectancy. This is due to the low success in the detection of this disease, as well as 
to a high resistance to therapies. Therefore, it is of major interest to set up biomark-
ers or biomarker panels dedicated to the earlier detection of the disease, as well as 
biomarker panels for the prediction of therapy outcomes. Many works have been 
dedicated to these aspects, including approaches based on genomics, proteomics, 
metabolomics, etc., or based on combination of such techniques.
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Liu et al. used a combination of MS-intensive methods such as isobaric tags for 
relative and absolute quantitation with two-dimensional liquid chromatography-
tandem mass spectrometry (iTRAQ-2DLC-MS/MS) and 1D-targeted LC-MS/MS, 
on serum samples from healthy people (normal control, NC), patients with benign 
diseases (BD), and PC patients to identify novel biomarkers of PC [123]. From 
more than 1000 identified proteins, 142 were identified as differentially expressed. 
For the diagnosis of PC, a novel biomarker panel consisting of apolipoprotein E 
(APOE), inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3), apolipoprotein 
A-I (APOA1), and apolipoprotein L1 (APOL1), in combination with CA19-9, 
statistically improved the sensitivity (95%) and specificity (94.1%), outperforming 
CA19-9.
Radon et al. used the LC-MS/MS analysis on urine samples from patients and 
controls and identified LYVE-1, REG1A, and TFF1 as candidate biomarkers [119]. 
Further the selected biomarkers were investigated by ELISA over a larger cohort 
(192 PDAC patients and 87 normal urine samples) and provided an AUC for the 
panel of 0.90, with the detection of PDAC in stages I–II.
Nigjeh et al. [124] applied a methodology of data-independent acquisition (DIA) 
[38] that included sample preparation with high reproducibility and separation by 
LC-MS/MS; they estimated the applicability in the detection of pancreatic cancer, 
based on a plasma spectral library consisting of over 14,000 identified peptides 
obtained from more than 2300 plasma proteins. The reliability of quantification 
was examined for the identified peptides, in constant retention times and signal 
intensity. The linear dynamic range and the lower limit of quantification were 
evaluated and pointed toward a critical role of the sample complexity for the 
optimization of DIA settings. Validation of the assay based on cohort of clinical 
plasma demonstrated the robustness and a unique advantage for targeted analysis 
of plasma samples for biomarker development.
In the study of Yoneyama et al. [125], LC-MS/MS proteomics was applied for 
the quantitation of plasma proteins, in combination with specific antibodies. 
The results showed that insulin-like growth factor-binding proteins (IGFBP)2 
and IGFBP3 display the potential to distinguish early-stage PDAC patients from 
normal controls and that IGFBP2 was increased in intraductal papillary mucinous 
neoplasms (IPMNs). Moreover, PDAC diagnosis based on a combination of IGFBP2 
and IGFBP3 and carbohydrate antigen 19-9 (CA19-9) is significantly more efficient 
compared to only CA19-9. These prove that IGFBP2 and IGFBP3 can represent 
supplemental or compensatory biomarkers to CA19-9 and by using this biomarker 
combination may improve the prognosis of PDAC patients.
Castillo et al. [126] examined analyzed exosomal surface proteins, using a 
combination of liquid chromatography and mass spectrometry. Simultaneously, 
PCR was applied on samples from 74 patients (a total of 136 exosome samples) to 
detect baseline KRAS mutation rates in patients subjected to therapy. The exosome 
proteomic analysis identified a set of biomarker candidates for PDAC: CLDN4, 
EPCAM, CD151, LGALS3BP, HIST2H2BE, and HIST2H2BF. In 44.1% of the patients 
under active therapy, KRAS mutations were detected in total (unsorted) exosomes; 
the yield increased to 73.0% when exosome capture was conducted based on 
selected biomarkers.
7. Applications of MS in colorectal cancer
Kirana et al. used a combination of 2D-DIGE and MALDI-TOF mass spec-
trometry for 125 tumor tissue samples in different TMA stages of CRC. Out of 
55 proteins with differential expression, a group of ten protein biomarkers was 
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selected, comprising HLAB, protein 14-3-3β, LTBP3, ADAMTS2, JAG2, and NME2; 
they were significantly associated with clinical parameters relevant for tumor 
progression, invasion, and metastasis. Kaplan-Meier survival curve demonstrated 
the marked expression of six proteins that could be associated with improved 
survival from CRC. The level of expression of HLAB, ADAMTS2, LTBP3, JAG2, and 
NME2 on tumor cells was associated with progression and invasion, metastasis, 
and CRC-specific survival; all these may be useful biomarkers for stratification of 
CRC patients regarding low and high risk of metastasis. A combination of microdis-
section with 2D-DIGE and MALDI-TOF MS was demonstrated to be useful in the 
identification of biomarkers for the prediction of the risk of liver metastases [127].
Suwakulsiri et al. applied quantitative mass spectrometry to examine the pro-
teomes of two classes of extracellular vesicles—exosomes and shed microvesicles 
(sMVs) [133]. Two populations of sMVs were investigated—released from primary 
(SW480) and metastatic (SW620) human isogenic-colorectal cell lines. One 
thousand two hundred ninety-five and one thousand three hundred proteins were 
identified in SW480-sMVs and SW620-sMVs, respectively, using quantitative mass 
spectrometry. Analysis of Gene Ontology identified processes of “cell adhesion” 
(CDH1, OCLN, CTN families), “signaling pathway” (KRAS, NRAS, MAPK1, 
MAP2K1), and “translation/RNA related” (EIF, RPL, HNRNP families) in both 
types of sMVs. Remarkably, SW480- and SW620-sMVs displayed distinct signatures; 
SW480-sMVs was enriched in ITGA/B, ANXA1, CLDN7, CD44, and EGFR/NOTCH 
signaling networks, while SW620-sMVs are higher in PRKCA, MACC1, FGFR4, and 
MTOR/MARCKS signaling networks. Jimenez et al. evaluated the proteins in small 
and large extracellular vesicles (SEVs and LEVs, respectively) [128], applying iso-
baric tag for relative and absolute quantitation liquid chromatography (iTRAQ-LC) 
[87] tandem mass spectrometry (MS) on EVs from colon cancer cell line (SW-480) 
and the lymph node metastatic line (SW-620) and a CRC patient primary culture. 
Bioinformatic analyses showed that SEVs contain higher levels of proteins involved 
in cell-cell junctions, cell-matrix adhesion, exosome biogenesis, and diverse signal-
ing pathways and that LEVs contain higher levels of proteins associated with the 
biogenesis of ribosomes and RNA biogenesis and processing and with metabolism.
Kit et al. [129] analyzed the patterns of expression for proteins implicated in cell 
signaling, using paired samples tumor/nontumor colon cancer patients, with the 
purpose of finding protein clusters capable of differentiation between patients hav-
ing non-metastatic and metastatic colon cancer. They found in tumoral mucosa nine 
proteins upregulated significantly: among these are protein kinase C gamma, c-Myc, 
MDM2, and pan-cytokeratin, while GAP1 was significantly downregulated. Pan-
cytokeratin and APP appeared upregulated in tumor compared to nontumor tissue 
and were thus included in the predictive cluster for discrimination of cancer type. All 
applied methods of regression/clustering confirmed the presence of increased con-
centrations of S-100b and phospho-Tau-pSer199/202, and their predictor value for 
non-metastatic colon cancer. Further investigations are required for the validation of 
potential protein markers for colon cancer development and metastatic progression.
Lee et al. [130] used liquid chromatography-tandem mass spectrometry (LC- 
MS/MS) analysis for identification of potential biomarkers in colon cancer. They 
identified tetraspanin 1 (TSPAN 1) as a potential noninvasive biomarker.
Liu et al. [123] applied MADLI-TOF-MS for the analysis of the N-glycome of IgG 
in patients with colorectal benign tumors, colorectal cancer, and normal individu-
als. The results identified nine IgG N-glycans that were differentially expressed in 
patient groups. Moreover, five of them were significantly modified in CRC patients 
in all TNM stages. Principal component analysis (PCA) indicated evident differen-
tiation between benign, cancer patients and normal individuals. The ROC analysis 
suggests that these five IgG N-glycans were correlated with the progression of 
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CRC. Analysis of IgG N-glycosylation suggests that core-fucosylation, sialylation, 
and sialo core-fucosylation were probably correlated with development of CRC.
Hu et al. [131] used stable isotope labeling by amino acids in cell culture (SILAC) 
technology. Thus, HCT116-I8 and HCT 116 cells were cultivated with either “light 
media” (Arg0, Lys0) or heavy media (Arg10, Lys8), for 7 days, followed by lysis 
of cultures, protein digestion, and MS analysis on an LTQ-Orbitrap mass spec-
trometer. The outcome of the study was Cdc42-Cdc42BPA signaling as prognostic 
biomarker and therapeutic target for colon cancer invasion. Also, the authors dis-
covered a decreased expression of E-cadherin and increased expression of vimentin 
in highly invasive cell lines.
Alvarez-Chaver et al. [132] investigated the proteomic profile of tumor and 
mucosa in CRC, using a combination of 2D electrophoresis and mass spectrometry, 
revealing nucleotide-diphosphate kinase as a candidate biomarker. They finally 
used an ELISA kit for the validation of the biomarker.
8. Conclusions
Mass spectrometry provides powerful instruments for the analysis of biologi-
cal systems, with dedicated instruments for different classes of analytes, such as 
proteomes, metabolomes, genomes, transcriptomes, etc. The power of such systems 
is usually backed by powerful bioinformatic tools, eventually playing at different 
levels (the “built-in” instrument that controls effectively the instrument), and the 
post-analytical bioinformatics tools that help in in-depth analysis and interpreta-
tion of findings.
We have tried to illustrate the state of the art concerning the available technology 
in MS for proteomics, and we have illustrated these with application in biomarker 
discovery in melanoma, glioblastoma, pancreatic cancer, and colorectal cancer.
Similar approaches are developed also for other solid cancers—such as gastric, 
hepatic, pulmonary, ovarian, or prostate—but, unfortunately, there is not enough 
space and time to approach them in this very chapter.
The core of the proteomic approaches is still based on two sample types: tissue 
(tumoral, peritumoral, and nontumoral—generally collected surgically or biop-
sies collected presurgically) and blood (most often, serum/plasma, more recently 
circulating tumor cells (CTCs) or circulating tumor stem cells (CTCS), and, in 
the last years, exosomes). Exosomes may represent an interesting option, since 
they bear significant cytosolic contents of the original cells (like nucleic acids and 
proteins) and also have a specific molecular surface signature of the originating 
cells. The major question on ECVs is represented by the amounts of such entities 
that can be recovered from small volumes of blood. Several other sample types 
were considered in the recent literature as sources for discovery of biomarkers 
and further as biological samples for diagnostics. One first example is represented 
by tears; it is considered that they have the overall load of plasma proteins, but 
devoid of the major ones (such as serum albumin), and could serve as biologi-
cal material for diagnostics, prognostics, and patient stratification. Other such 
samples are saliva and urine; as in the case of tears, their collection is completely 
noninvasive.
Once one or several biomarkers are identified, next stages of pre-validation and 
validation are required, usually these will be achieved using non-MS techniques, 
such as ELISA, Western blot, or the use of multiplex platforms (Luminex, Meso 
Scale, etc.). One major problem in the progress toward clinical application is 
represented by the existence of equipment and detection kits validated for such 
applications, and this might represent a major problem for the future.
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Finally, we want to encourage all who can implicate in cancer proteomics, thus 
accelerating the progress in knowledge.
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